Recombinant VEGF (Bevacizumab Biosimilar) anticorps

N° du produit ABIN7200653

Détail du produit anti-VEGF (Bevacizumab Biosimilar) anticorps

Antigène: VEGF (Bevacizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp VEGF (Bevacizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Fonction: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody

Specificité: The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.

Attributs du produit: Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur VEGF (Bevacizumab Biosimilar)

Antigène: VEGF (Bevacizumab Biosimilar)

Abstract: VEGF (Bevacizumab Biosimilar) Produits

Synonymes: anticorps MVCD1, anticorps VEGF, anticorps VPF, anticorps vascular endothelial growth factor A, anticorps VEGFA

Classe de substances: Biosimilar

Sujet: Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.